MX2023001912A - Tratamiento de la sepsis con moduladores de pcsk9 y ldlr. - Google Patents

Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.

Info

Publication number
MX2023001912A
MX2023001912A MX2023001912A MX2023001912A MX2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A
Authority
MX
Mexico
Prior art keywords
sepsis
ldlr
pcsk9
methods
modulators
Prior art date
Application number
MX2023001912A
Other languages
English (en)
Inventor
Amy Damask
Garen Manvelian
Aris Baras
Julie Horowitz
Charles Paulding
Manuel Allen Revez Ferreira
Luca Andrea Lotta
Michael Cantor
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023001912A publication Critical patent/MX2023001912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Telephone Function (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona métodos para el tratamiento de sujetos que tienen sepsis, SIRS, choque séptico y/o MODS, métodos para la identificación de sujetos que tienen un mayor riesgo de desarrollar sepsis, SIRS, choque séptico y/o MODS, y métodos para la detección de polipéptidos variantes y moléculas de ácidos nucleicos variantes de receptor de lipoproteínas de baja densidad (LDLR) y/o proproteína convertasa subtilisina/kexina tipo 9 (PCSK9).
MX2023001912A 2020-08-25 2021-08-25 Tratamiento de la sepsis con moduladores de pcsk9 y ldlr. MX2023001912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063069789P 2020-08-25 2020-08-25
PCT/US2021/047502 WO2022046873A1 (en) 2020-08-25 2021-08-25 Treatment of sepsis with pcsk9 and ldlr modulators

Publications (1)

Publication Number Publication Date
MX2023001912A true MX2023001912A (es) 2023-07-10

Family

ID=77775030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001912A MX2023001912A (es) 2020-08-25 2021-08-25 Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.

Country Status (10)

Country Link
US (1) US20220064652A1 (es)
EP (1) EP4204563A1 (es)
JP (1) JP2023539742A (es)
KR (1) KR20230057410A (es)
CN (1) CN116171161A (es)
AU (1) AU2021335200A1 (es)
CA (1) CA3191030A1 (es)
IL (1) IL300439A (es)
MX (1) MX2023001912A (es)
WO (1) WO2022046873A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
US10323076B2 (en) * 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CA3035875A1 (en) * 2016-09-20 2018-03-29 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants
CN113166101A (zh) * 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物

Also Published As

Publication number Publication date
CN116171161A (zh) 2023-05-26
CA3191030A1 (en) 2022-03-03
US20220064652A1 (en) 2022-03-03
EP4204563A1 (en) 2023-07-05
WO2022046873A1 (en) 2022-03-03
IL300439A (en) 2023-04-01
JP2023539742A (ja) 2023-09-19
KR20230057410A (ko) 2023-04-28
AU2021335200A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
Mertens et al. Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
Chen et al. Identification of cleavage sites leading to the shed form of the anti-aging protein klotho
Hung et al. Degradation of postsynaptic scaffold GKAP and regulation of dendritic spine morphology by the TRIM3 ubiquitin ligase in rat hippocampal neurons
Okerberg et al. High-resolution functional proteomics by active-site peptide profiling
US11268127B2 (en) Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
ATE414169T1 (de) Methoden zur detektion von nukleinsäuren unter verwendung von zymogenen und dazugehörige kits
WO2014144080A3 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
MX2023001912A (es) Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.
Sameni et al. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ
Hawkins et al. Fluorometric immunocapture assay for the specific measurement of matrix metalloproteinase-9 activity in biological samples: application to brain and plasma from rats with ischemic stroke
MX2021008797A (es) Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
Xie et al. SIX1 is upregulated in gastric cancer and regulates proliferation and invasion by targeting the ERK pathway and promoting epithelial‐mesenchymal transition
ATE291736T1 (de) Verfahren zur bestimmung des zustandes von keratin enthaltenden materialien
Brinet et al. An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of Aβ1–42 peptide oligomerization: Application to anti‐Alzheimer's drug discovery
Lanchec et al. The type II transmembrane serine protease matriptase cleaves the amyloid precursor protein and reduces its processing to β-amyloid peptide
DK0862622T3 (da) Fremgangsmåde til identifikation af forbindelser, der vekselvirker med RAC-proteinkinase
WO2004029285A3 (en) Methods for detecting endocrine cancer
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
ATE293254T1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
Hernandez et al. The role of nerve fibers in the tumor immune microenvironment of solid tumors
ATE238551T1 (de) Homogene nachweisverfahren zur bestimmung der phosphorylierungsaktivitäten von biologischem material
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
MX2021011015A (es) Tratamiento de la hiperglucemia con inhibidores del miembro 5 de la familia 39 de los transportadores de solutos (slc39a5).
WO2005107803A3 (en) Methods of determining the prognosis and treatment of subjects with lung cancer